Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2000

View Archived Issues

MedImmune reports significant progress during second quarter

Acetylcysteine useful in preventing contrast agent-induced reductions in renal function

IB-367 active against microflora associated with oral mucositis

Sitaxsentan causes selective pulmonary vasodilatation in chronic heart failure

Antiviral action of aciclovir lipid prodrug assessed against woodchuck hepatitis virus

Atrix rapidly enrolls patients in clinical trials

Phase II SBIR grant awarded to Aurora for immunomodulatory drug discovery

Potent new inhibitor of p210Bcr-Abl tyrosine kinase with selectivity for Bcr-Abl-positive leukemia

Novel cell adhesion inhibitor acting independently of NF-kappaB identified by Kowa

TxA2 antagonism and antiplatelet effects of new torasemide derivative BM-531

Alza, Crescendo report substantial progress this year

Trial in healthy subjects confirms safety and pharmacological effects of TF-505

New immunomodulator promising for the management of HIV/AIDS

Bexxar enters phase II trial for intermediate-grade NHL

VRCTC-310-Onco enhances serum antiinflammatory cytokine production in humans

Maxygen and Karolinska Institute to develop novel allergy therapeutics

Cubist ready to commence further phase III trials of Cidecin

Pharmacia drops leridistim research program

TNF-alpha inhibitors and use in therapy of joint inflammation, asthma

New dosage form, indication approved for Bayer's cerivastatin

Promising phase Ib results shown for Isotechnika's ISAtx-247

Recently issued patent covers new nicotinic acetylcholine receptor antagonists

AstraZeneca presents novel antiinflammatory compounds for asthma, etc.

Nonpeptide GLP-1 antagonists and their potential uses described in recent patent

Novel classes of calcium-activated SK/IK/BK channel modulators designed at NeuroSearch

New inhibitors of Ras oncogene farnesylation in the Merck pipeline

Antex evaluates dosing schedule in phase Ib/II trial of Helivax

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...